We Can Stop Duplicate Financing Fraud This Year, Says International Chamber of Commerce United Kingdom as New Initiative Launched
The International Chamber of Commerce United Kingdom (ICC United Kingdom) has announced a new initiative to strengthen the UK finance industry against the impacts of duplicate financing fraud. The Centre for Digital Trade and Innovation (C4DTI)-led initiative will leverage ICC United Kingdom’s convening capabilities to deliver this flagship project under the C4DTI’s Shutting fraudsters out of trade workstream in partnership with MonetaGo.
Duplicate financing is defined as fraud by which fraudsters get the same transaction financed multiple times. Today, a fraudster can go to multiple banks and have the exact same trade financed, without the banks having the ability to cross check. Regulation around confidentiality hinders banks from sharing information on deals they have financed with other banks, creating a grey area that fraudsters leverage to finance the same transaction multiple times. It is a fraud typology impossible to detect via existing siloed AI and KYC tools and requires an innovative and collaborative ecosystem approach. Duplicate financing has therefore syphoned billions of dollars from the financial services community globally.
By the end of 2023, UK banks will be able to ensure that a transaction has not been financed multiple times in the banking community. Although some details remain confidential, the majority of trade banks in the UK have agreed to take part in the project, with more expected to join in due course. This would make the UK the first G7 economy to tackle this issue, saving hundreds of millions of pounds in lost funding that can be better spend facilitating real trade transactions. In the context of a global trade finance gap of $1.7 trillion, it is crucial that penny goes to legitimate businesses.
"Technological innovation will change the game in finance over the next five years, with the UK taking a leading charge in MLETR legislative reforms. This will unlock much-needed innovation which will revolutionise finance," said Chris Southworth, Secretary General of ICC United Kingdom.
"Not all innovations require years to deliver value, and eliminating duplicate financing fraud, in partnership with MonetaGo, is a great example of an existing solution that will have a significant impact in the short term. ICC United Kingdom is uniquely positioned to help accelerate the elimination of duplicate financing fraud, with the aim that every financed Pound makes its way to a business raising finance legitimately by the end of 2023."
To combat duplicate financing fraud, ICC United Kingdom has partnered with financial technology provider MonetaGo. The firm's service has been live since 2018, processing millions of transactions in Asia and actively preventing duplicate financing in receivables discounting and invoice finance. The service is available on SWIFT's new API Gateway service offering, enabling its 11,000+ member financial institutions to access the MonetaGo service. Built from the ground up on international standards, this fraud prevention utility connects to a wide array of financing platforms.
Notes to editors:
ICC United Kingdom is the UK representative office of the International Chamber of Commerce, the largest world business organisation representing 45 million companies in 100 countries. ICC’s mission is to promote inclusive, sustainable and green trade. Its rules underpin $25 trillion of global trade.
ICC United Kingdom represents the voice of British business at the inter-governmental level, including the United Nations, G20 and World Trade. Organization. For further information, please visit iccwbo.uk .
The Centre for Digital Trade and Innovation (C4DTI) is an ICC United Kingdom-led, global initiative based in Teesside in the North-East of England. Launched in April 2022 as a public, private partnership, its mission is to accelerate the digitalisation of UK trade and promote the adoption of interoperable legal, standards and rules frameworks. For further information, please visit c4dti.co.uk .
MonetaGo's Secure Financing solution enables banks and traditional financiers as well as non-bank financial institutions, fintechs and trade finance funds to check for duplication of financing requests linked to invoices, bills of lading, air waybills, warehouse receipts, purchase orders and other trade-related documents.
Since entering full production in 2018, the Secure Financing system has processed over 4 million transactions and has been integrated into SWIFT's API-enabled infrastructure as the first third-party service on SWIFT, providing its member institutions with an important tool to combat duplicate financing fraud in trade and supply chain finance.
MonetaGo has recently been awarded Best Fintech Startup in Trade 2022 by Global Trade Review, while its Secure Financing solution has been recognised as Best Solution in Trade Finance at the AMTD DigFin Innovation Awards at the Hong Kong Fintech Week 2021, and as Most Effective Bank-Fintech Partnership at the IBS Intelligence Global Fintech Innovation Awards 2021. For further information, please visit monetago.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230207005735/en/
Contact information
Michael Keating; press@iccwbo.uk; +44 7542 935329
Matt Stapleton; matt@monetago.com; +65 9654 9402
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Sonrotoclax Data at ASH 2025 Confirm Foundational Potential Across B-cell Malignancies8.12.2025 01:00:00 EET | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new data on sonrotoclax, a next-generation investigational BCL2 inhibitor, demonstrating meaningful clinical benefit as monotherapy and in combination across B-cell malignancies. These data were featured at the 67th American Society of Hematology (ASH) Annual Meeting & Exposition in Orlando, Florida. The five presentations highlight durable responses in heavily pretreated patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) and additional studies showing deep, rapid, and sustained undetectable minimal residual disease (uMRD) rates with sonrotoclax-based combinations in patients with treatment-naive chronic lymphocytic leukemia (CLL), highlighting the foundational potential of this medicine. “The data we’re presenting at ASH 2025 are redefining what physicians can expect from sonrotoclax as a next-generation BCL2 inhibitor,” said Amit Agarwal, M.D., Ph.D., Chief Medical
Hemato-Oncology Trials: AOP Health Presents New Results at Top Congress ASH7.12.2025 18:00:00 EET | Press release
AOP Health continues to advance its clinical research program in myeloproliferative neoplasms, a special group of rare blood cancers. The company, specialized in rare diseases, presented the results of two scientific investigations at the 67th American Society of Hematology Association (ASH) Annual Meeting 2025 held in Orlando, FL, USA. The results provide new insights in treatment strategies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251207587915/en/ Dr. Martin Steinhart, CEO AOP Health; Photo credit: AOP Health/Studio Koekart ROP-ET and BESREMI PASS One of the clinical studies, ROP-ET, examined the use of ropeginterferon alfa-2b in people with essential thrombocythemia (ET), a disease in which the body produces too many platelets. The trial, a prospective, multicenter, single-arm phase III study, investigated the safety and efficacy of ropeginterferon alfa-2b in ET patients unable to receive available cytoreductive th
CoMotion GLOBAL 2025 Launches in Riyadh: Global Mobility Leaders Unite in Saudi Capital to Chart Urban Future7.12.2025 14:00:00 EET | Press release
Riyadh is rapidly becoming one of the world's most ambitious urban mobility laboratories, where next-generation technologies move from blueprint to real-world deployment on city streets at unprecedented scale. CoMotion GLOBAL 2025, the world's most influential gathering of urban mobility leaders, opens today in Riyadh for a three-day summit bringing together innovators from Africa, Asia, Europe, the Americas, and the Middle East. Running December 7-9, the event will explore how electrification, autonomy, AI-enabled transport, and giga-project urbanism are reshaping cities worldwide. The summit will spotlight everything from high-performance EVs and breakthrough autonomous fleets to emerging-market transport solutions and new mobility models, demonstrating how the Kingdom is opening new pathways for global mobility leadership. Strategic Partnerships Powering the Summit CoMotion GLOBAL 2025 is hosted by the Saudi Conventions & Exhibitions General Authority (SCEGA), supported by key Saudi
Deciphera Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera at the 67 th American Society of Hematology (ASH) Annual Meeting6.12.2025 16:30:00 EET | Press release
Deciphera Pharmaceuticals, a member of Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the oral presentation of positive results from the Phase 2a IMPRSSION study of sapablursen in patients with polycythemia vera (PV) at the 67th American Society of Hematology (ASH) Annual Meeting, taking place December 6-9, 2025, in Orlando, FL. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251206361611/en/ The results were presented by Ionis Pharmaceuticals, who discovered and developed sapablursen and conducted the IMPRSSION study. In March 2025, Ionis and Ono entered into a license agreement in which Ono obtained exclusive global rights for the development and commercialization of sapablursen. “In the treatment of PV, phlebotomy and cytoreductive therapy are performed as treatments for preventing thrombosis. Phlebotomy is the most common treatment for PV, in which blood
Protagonist and Takeda Present Longer-Term Data at ASH 2025 Showing Rusfertide Delivers Durable Response and Hematocrit Control in Polycythemia Vera6.12.2025 16:30:00 EET | Press release
Protagonist Therapeutics, Inc. (“Protagonist”) (NASDAQ:PTGX) and Takeda (TSE:4502/NYSE:TAK) announce that new 52-week results from the pivotal Phase 3 VERIFY study evaluating rusfertide in patients with polycythemia vera (PV) will be presented in an oral presentation at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition. These findings further reinforce rusfertide’s efficacy and safety and demonstrate durability of response, with 61.9% of patients continuously treated with rusfertide maintaining absence of phlebotomy eligibility from baseline to Week 52. “The 52-week data demonstrated the sustained efficacy of rusfertide, reducing the need for patients to receive phlebotomy while maintaining hematocrit control,” said Dr. Andrew T. Kuykendall, M.D., VERIFY Lead Investigator and Associate Member in the Department of Hematology at Moffitt Cancer Center. “The 32-week VERIFY primary results were already promising, and this deeper understanding of the durability of r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
